Browse News
Filter News
Found 564,920 articles
-
The U.S. Food and Drug Administration approved Impact’s Inrebic for the treatment for adult patients with certain types of myelofibrosis, cancers of the bone marrow.
-
Although some of the top-selling drugs in the world are facing patent cliffs between now and then, many of them are still projected to continue being big sellers between now and 2024.
-
Current rules set by the FDA allow companies to assess whether or not long-term follow-ups are required based on risk factors determined by the company.
-
The researchers are currently optimizing the drug and similar drugs so they can advance to human clinical trials.
-
BioSpace Movers & Shakers, Aug. 16
8/16/2019
Biopharma companies strengthen their executive ranks and boards with new additions. -
The FDA approved Rozlytrek for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer. Also, Rozlytrek secured accelerated approval for the treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance...
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
When it comes to potential pricing controls of the pharmaceutical industry, Jim Greenwood, chief executive officer of BIO, grimly stated that “nothing good” was going on in the halls of power in Washington, D.C.
-
The device is most likely to be used in optogenetics, where light is used to stimulate cellar activity. It may also have functionality for monitoring tissues and cells during medical procedures.
-
Gilead Sciences COMPASS Initiative® Begins Accepting "Transformative Grant" Applications from Organizations Fighting HIV in the South
8/16/2019
Today, the Gilead COMPASS (COMmitment to Partnership in Addressing HIV/AIDS in Southern States) Initiative®— announced a request for proposals (RFP) from organizations working to fight stigma, increase access to health services, and increase local leadership for those living with HIV in the South.
-
Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2019
8/16/2019
Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its financial results for the second quarter ended June 30, 2019.
-
Jeff Berg Assumes Top Leadership Role at AbelsonTaylor With Appointment to President
8/16/2019
For the first time in its 38-year history, Chicago-based AbelsonTaylor, one of the world's premier health and wellness advertising agencies, has a new president
-
FDA approves new device to improve symptoms in patients with advanced heart failure
8/16/2019
The U.S. Food and Drug Administration today approved the Barostim Neo System for the improvement of symptoms in patients with advanced heart failure who are not suited for treatment with other heart failure devices, such as cardiac resynchronization therapy.
-
Cardiovascular Systems Presents LIBERTY 360° Three-Year Outcomes at 2019 Amputation Prevention Symposium
8/16/2019
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease (PAD and CAD), presented three-year outcomes from its LIBERTY 360° study in a late-breaking presentation at the 2019 Amputation Prevention Symposium (AMP) in Chicago.
-
Investor Alert: Kaplan Fox Investigates Myriad Genetics, Inc.
8/16/2019
Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors who purchased shares of Myriad Genetics, Inc. ("Myriad" or the "Company") (NASDAQ: MYGN).
-
CVRx Receives FDA Approval for World's First Heart Failure Neuromodulation Device
8/16/2019
CVRx, Inc., a private medical device company, announced today that it has received Premarket Approval (PMA) from the United States Food and Drug Administration (FDA) to market its BAROSTIM NEO device for heart failure in the United States.
-
Oncopeptides Announces Acceptance of Data for Presentation at International Myeloma Workshop, September 12-15
8/16/2019
Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today the acceptance of an oral late breaking presentation providing updated melflufen data from the Phase 2 pivotal OP-106 HORIZON study as well as two poster presentations at the 17th International Myeloma Workshop (IMW) meeting (September 12-15, Boston, Massachusetts, USA).
-
Cemvita Factory and Oxy Low Carbon Ventures Announce Investment Agreement to Advance Innovative Low-Carbon Technology
8/16/2019
Cemvita Factory, a carbon-negative company, today announced that it has received equity investment from Oxy Low Carbon Ventures to support the commercialization of new bio-engineered pathways that use CO2 as the feedstock for sustainable production of intermediate chemicals and polymers.
-
IgA Nephropathy Patients Invited to Speak About their Disease to the FDA
8/16/2019
The many voices of patients with IgA nephropathy, a chronic kidney disease, will come together on Monday, August 19, during an Externally-led Patient-focused Drug Development (EL-PFDD) meeting in Hyattsville, MD.
-
Health Perspectives Group Recognized for Third Consecutive Year on Inc. 5000 List of America's Fastest-Growing Private Companies
8/16/2019
Health Perspectives Group, a health engagement company that unites patients, providers and the companies that serve them, has been ranked for the third year in a row as one of America's fastest-growing private companies by Inc. Magazine on its 38th annual Inc. 5000 list.